Laura Basterretxea Badiola
Laura Basterretxea Badiola
MEDICAL ONCOLOGY SPECIALIST
Oncología Médicaen/specialities/oncologia-medica
See more specialists on
Guipúzcoaguipuzcoa
en/medical-staff/oncologist
Dr. Laura Basterretxea Badiola is a leading specialist in Medical Oncology , currently practicing at the Policlínica Gipuzkoa . Her academic background includes a PhD in Medicine and Surgery from the Universidad del País Vasco, obtained in 2018. Throughout her career, she has made significant contributions to the field of oncology, excelling in research and the publication of clinical studies. Among her publications is the article "Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer," published in the Journal of Clinical Medicine in April 2021. Dr. Basterretxea is also a member of the Hematology-Oncology Group at the Biodonostia Health Research Institute (IIS Biodonostia), where she collaborates on advancing cancer research. Her commitment to oncology is reflected in her participation in research projects such as "ONKO-FRAIL," focused on the personalization of interventions in oncogeriatrics, funded by the Basque Government's Department of Health.
Key information
- Call for proposals for intensification of research activity2018
- Latest Publication:Characteristics and treatments patterns of patients with an advanced or metastatic urothelial carcinoma (UC) after failure of a platinum-based chemotherapy (CT): results of the European observational study EPICURE
- Belongs to:Grupo Español de Tumores Genitourinarios
Professional Details
Policlínica Gipuzkoa
SPECIALIST PHYSICIAN MEDICAL ONCOLOGY
January 2019
Study
Bachelor of Medicine and Surgery
university, Universidad de Navarra
1998
Doctorate
Universidad del País Vasco
2018
Another qualification
Master in comprehensive management of head and neck cancer
university
KIDNEY CANCER IN THE SPOTLIGHT
March 2023
UPDATE ON GENITOURINARY ONCOLOGY ASCO GU 2023
GO NORTE
February 2023
RENALINK. Advances in oncology.
ECO-Fundacion para la excelencia y calidad de la oncología
February 2023
UPDATE ON GENITOURINARY ONCOLOGY ASCO GU 2022
GO NORTE
February 2022
TRANSLATING KIDNEY CANCER EVIDENCE INTO CLINICAL PRACTICE
GO NORTE
October 2021
CHALLENGES IN THE MANAGEMENT OF KIDNEY CANCER
GO NORTE
June 2021
PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform.
Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study.
Prospective clinical trial. Prospective study of the usefulness of liquid biopsy as a predictive and prognostic factor in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy.
Prospective observational study to evaluate the predictive value of response to Tyrosine Kinase Inhibitors (TKIs) of a series of bone biomarkers in patients with renal cancer and bone metastases.
Phase II clinical trial. Randomized phase II study of vemurafenib and cobimetinib administered continuously or intermittently, in patients with advanced unresectable or metastatic melanoma with the BRAF V600 mutation.
Prospective observational study to determine circulating endothelial cell (CEC) levels in patients with advanced clear cell renal carcinoma without radiological progression after 3 months of first-line treatment according to usual clinical practice.
SOGUG Group
Randomized, double-blind, phase III clinical trial. IMvigor010
Randomized, double-blind, phase III clinical trial. Javelin HaN
Ensayo clínico fase III doble ciego randomizado. Adjuvant axitinib treatment of renal cancer: a randomized double-blind phase 3 study of adjuvant axitinib vs. placebo in subjects at high risk of recurrent RCC.
Prospective epidemiological study. ABSOLUT-BRAF study. Epidemiological study on the BRAF V600 mutation in a Spanish population diagnosed with metastatic melanoma.
Roche Farma, S.A.
Estudio clínico observacional retrospectivo, RENO. Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain.
Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients: CABOMAYOR study.
Spanish Oncology Genitourinary Group - SOGUG
2019
Characteristics and treatments patterns of patients with an advanced or metastatic urothelial carcinoma (UC) after failure of a platinum-based chemotherapy (CT): results of the European observational study EPICURE
Scientific article
Comparison of stem cell signaling pathways in long-term responders (LR) versus primary refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under sunitinib (SU) treatment (SULONG study)
Scientific article
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer
Scientific article
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific article
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
Scientific article
Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial
Scientific article
Integrated analysis of mRNA and miRNA to unravel novel mechanisms of sunitinib long term response in mRCC
Scientific article
Intermittent BRAF inhibition in advance BRAF mutated melanoma results of a phase II randomized trial
Scientific article
Novel agents sequencing following first-line docetaxel in mCRPC patients: CAPRO study
Scientific article
Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study
Scientific article
Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy
Scientific article
Predictive factors for simultaneous distant metastasis in head and neck cancer patients during the diagnostic work-up
Scientific article
Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists
Scientific article
Prospective assessment of circulating endothelial cells (CECs) as pharmacodynamic marker in first line clear cell renal cell carcinoma (CCRCC): The CIRCLES study
Scientific article
PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform
Scientific article
RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain
Scientific article
Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma
Scientific article
Undertreatment and overtreatment in older patients treated with chemotherapy
Scientific article
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study
Scientific article
Grupo Español de Tumores Genitourinarios
Sociedad Española de Oncología Médica
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Call for proposals for intensification of research activity
Gobierno Vasco
Basque Government grant for research in Oncogeriatrics
Gobierno Vasco
English
B2
Basque
C1
Make an appointment with this professional
Vídeos de
Consulta el contenido multimedia de este profesional.
Hospitals
Book an appointment now at one of our hospitals.
Policlínica Gipuzkoa
Paseo Miramón, 174
20014 Donostia Gipuzkoa
Articles on
Browse the latest articles on Tu canal de salud.
¿No tienes seguro de salud?
Con nuestros Planes de Salud Quirónsalud Connect tendrás un médico de medicina general todos los días las 24 horas. Y además gestor personal y medición facial de constantes vitales.